Medigene Reports Financial Results and Corporate Update for Q3 2023

Focus on executing the strategic plan and delivering shareholder valueFirst MDG2011 pre-clinical data support potential in solid tumor therapyExpansion of patent portfolio and license agreement for...

Related Keywords

China ,Madrid ,Spain ,Japan ,Hongsheng ,Hubei ,United States ,Pamela Keck ,Doloresj Schendel ,Planegg Martinsried ,Hongsheng Sciences ,Company Quarterly Statement ,Research Development ,European Patent Office ,European Society For Medical Oncology ,End To Platform ,Prime Standard ,European Society ,Medical Oncology ,Chief Executive Officer ,Corporate Highlights ,Executive Management Board ,Development Highlights ,Driving Force ,Cellular Oncology ,Markets ,